Report
Eli Lilly and Co
Lilly Corporate Ctr
Drop Code 1094, Lilly Corporate Ctr
Phone: (317) 276-2000p:317 276-2000 INDIANAPOLIS, IN  46285-0001  United States Ticker: LLYLLY


Lilly and Ypsomed collaborate to advance automated insulin delivery system in diabetes


December 03 -- Eli Lilly (NYSE:LLY) and Ypsomed (OTC:YPHDF) announce a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions.

  • Under the terms of agreement, Lilly will commercialize the system, currently in development and will include an insulin pump developed and manufactured by Ypsomed.
  • Ypsomed's insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife YpsoPump, this pump stands out for its small size and its unique, icon-based touch screen.
  • Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring in the U.S. and Europe. This pump will use pre-filled insulin cartridges for Lilly's rapid-acting insulins.
  • Ypsomed plans to submit mylife YpsoPump for FDA clearance for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.

Related Businesses
- - Customer

Copyright © 2024 by CreditRiskMonitor.com (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by CreditRiskMonitor.com, Inc. Except as expressly permitted by CreditRiskMonitor.com, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that CreditRiskMonitor.com, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of CreditRiskMonitor.com, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by CreditRiskMonitor.com, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of CreditRiskMonitor.com, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable.  CreditRiskMonitor.com, Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Thursday, March 28, 2024